Todos Medical Ltd.

75 articles with Todos Medical Ltd.

• Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen

  5/4/2021

  Company sees this new dosing regimen of 60 pills over 5 days as optimal for Tollovid, the Company’s 3CL protease inhibitor botanical dietary supplement that helps to support and maintain healthy immune function

• Todos Medical Acquires Provista Diagnostics and Its Proprietary Videssa Breast Cancer Blood Test

  4/22/2021

  Todos plans to commercialize Videssa in late 2021 to reduce unnecessary biopsies in the $7.19 billion mammogram naïve market and integrate it into its TBIA Platform   Provista Diagnostics’ testing lab in the Atlanta, Georgia area is currently performing COVID-19 testing, that will be automated to significantly increase processing capacity Todos expects to employ testing methodologies to expand Provista’s capabilities regarding COVID variant identification

• Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients

  4/19/2021

  First 10 patients dosed in 77 patient randomized, double blind, placebo controlled Phase 2 Clinical Trial at Shaare Zedek Medical Center in Jerusalem, Israel Data from randomized, placebo controlled, open label Phase 1b trial in 27 hospitalized COVID-19 patients supports dose selection for the Phase 2 Clinical Trial Company to include its proprietary 3CL protease enzymatic assay (“TolloTest™) as exploratory theranostic biomarker

• Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY

  3/29/2021

  Automation solution increases processing capacity to 6,000 PCR tests per day, expandable to 12,000 daily tests with minor upgrades

• Todos Medical Applauds Senate and House Passage of the American Recovery Act

  3/11/2021

  Todos Medical, Ltd., an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening, diagnosis and immune support, as well as developing blood tests for early detection of cancer and Alzheimer’s disease, applauded the Senate and House’s passage of the American Recovery Act.

• Todos Medical Announces Strategic Investment by Yozma Group Korea

  1/25/2021

  Todos Medical (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced a $3.4 million strategic investment (the “Investment”) from tech-focused venture capital firm Yozma Group Korea (“Yozma”). “Yozma Group Korea is p

• Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020

  1/11/2021

  Todos Medical (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced $4.8 million in sales for the month of December 2020, which represents a 50% month over month increase from November 2020.

• Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020

  12/2/2020

  Todos Medical (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced $3.2 million in sales for the month of November 2020. This represents a 269% increase in monthly sales as compared with October 2020. The majority o

• Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

  11/20/2020

  Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease

• Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay

  11/18/2020

  Todos Medical (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Te

• Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs

  11/17/2020

  Todos Medical (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced the completion of clinical validation and CLIA certification for MOTO+PARA’s mobile lab. The Company’s mobile CLIA lab partner, Integrated Hea

• Todos Medical Announces $867,000 in Sales for October 2020

  11/12/2020

  Sales primarily made up of extraction reagents   Wisconsin client received request from State of Wisconsin to increase PCR testing by 200%   Liquid handlers that increase capacity to 20,000 qPCR (4x of current capacity) tests per day delivered to Wisconsin client   Wisconsin client per test revenue expected to increase 267% upon addition of qPCR kits to its weekly order in second half of November once liquid handler validation is complete

• Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep(R) Point-of-Care Covid-19 Antibody Tests

  10/22/2020

  Todos Medical (TOMDF) an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimers disease, along with Adial Pharmaceuticals, Inc.

• Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests

  10/22/2020

  Todos Medical (OTCQB:TOMDF) (“Todos”) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, along with  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the developmen

• UPDATE:  Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020

  10/14/2020

  §   Received first payments from $47.5 million contract with Wisconsin client on October 9, 2020 §   Wisconsin client upped avg. kit purchases from 2,100+/day to 3,500+/day on October 12, 2020 §   Todos has completed equipment purchases for signed Q3/20 reagent supply agreements §   Existing contracts have the potential to deliver over $60 million in revenue to Todos by end Q2/2021 NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire   --  Todo

• Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020

  10/13/2020

  Received first payments from $47.5 million contract with Wisconsin client on October 9, 2020   Wisconsin client upped avg. kit purchases from 2,100+/day to 3,500+/day on October 12, 2020   Todos has completed equipment purchases for signed Q3/20 reagent supply agreements   Existing contracts that have the potential to deliver over $60 million in revenue to Todos by end Q2/2021 NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire   -- Todos Me

• Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health

  10/7/2020

  Todos Medical Ltd. announced that it has entered into an exclusive supply agreement with U.S. national mobile CLIA laboratory company Integrated Health LLC operating MOTOPARA Foundation’s mobile biosafety level 3-built laboratories developed to address the global COVID-19 pandemic.

• Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States

  9/30/2020

  Todos Medical Ltd. (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an exclusive branding and distribution agreement with Australia-headquartered Melbourne Biotech, a US FDA-reg

• Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million

  9/22/2020

  Todos Medical Ltd. announced that it has rapidly expanded its agreement with a Wisconsin-based laboratory to supply it with the necessary testing equipment and supplies to ramp up to 12,000 tests a day, for a total contract value of $47.5 million in reagent sales by Todos Medical over the next seven months.

• Todos Medical CEO Releases Letter to Shareholders

  9/18/2020

  Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and institutional Q1/2020 convertible note holders sign temporary lock-up agreement NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an  in vitro